Asheville, NC

Digestive Health Partners

Ulcerative Colitis

Colorectal Cancer

Crohn Disease

Ulcer

Liver Cancer

Colitis

Hepatitis B

Hepatocellular Carcinoma

Carcinoma

Mirikizumab

Exact Sciences Corporation

Guardant Health

Janssen (J&J Innovative Medicine)

Lilly

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Digestive Health Partners | Asheville, NC

Site insights

Work at this site?

Active trials

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-URGE)

Trial sponsors